NasdaqGS:AXGT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Axovant Gene Therapies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AXGT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

AXGT

0.2%

US Biotechs

2.6%

US Market


1 Year Return

-54.8%

AXGT

27.0%

US Biotechs

15.4%

US Market

Return vs Industry: AXGT underperformed the US Biotechs industry which returned 29.1% over the past year.

Return vs Market: AXGT underperformed the US Market which returned 16.2% over the past year.


Shareholder returns

AXGTIndustryMarket
7 Day0%0.2%2.6%
30 Day11.6%-2.4%6.1%
90 Day-0.3%7.2%16.6%
1 Year-54.8%-54.8%28.3%27.0%17.8%15.4%
3 Year-98.3%-98.3%31.7%27.2%43.9%34.7%
5 Year-96.8%-96.8%-1.4%-7.1%76.2%57.3%

Price Volatility Vs. Market

How volatile is Axovant Gene Therapies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Axovant Gene Therapies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AXGT ($2.99) is trading below our estimate of fair value ($8.88)

Significantly Below Fair Value: AXGT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AXGT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AXGT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXGT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXGT is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Axovant Gene Therapies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

24.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXGT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXGT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXGT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AXGT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AXGT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AXGT's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Axovant Gene Therapies performed over the past 5 years?

5.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXGT is currently unprofitable.

Growing Profit Margin: AXGT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXGT is unprofitable, but has reduced losses over the past 5 years at a rate of 5.9% per year.

Accelerating Growth: Unable to compare AXGT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXGT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.3%).


Return on Equity

High ROE: AXGT has a negative Return on Equity (-117.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Axovant Gene Therapies's financial position?


Financial Position Analysis

Short Term Liabilities: AXGT's short term assets ($85.4M) exceed its short term liabilities ($32.0M).

Long Term Liabilities: AXGT's short term assets ($85.4M) exceed its long term liabilities ($79.0K).


Debt to Equity History and Analysis

Debt Level: AXGT's debt to equity ratio (25.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AXGT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXGT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXGT has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 8.2% each year.


Next Steps

Dividend

What is Axovant Gene Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AXGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AXGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Pavan Cheruvu (38 yo)

2.5yrs

Tenure

US$2,868,749

Compensation

Dr. Pavan Cheruvu, M.D., has been Chief Executive Officer of Axovant Gene Therapies Ltd. (formerly known as Axovant Sciences Ltd.) since February 12, 2018 and as its Director since September 26, 2018. Dr. ...


CEO Compensation Analysis

Compensation vs Market: Pavan's total compensation ($USD2.87M) is above average for companies of similar size in the US market ($USD606.98K).

Compensation vs Earnings: Pavan's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Pavan Cheruvu
CEO & Director2.5yrsUS$2.87m0.14%
$ 171.8k
David Nassif
CFO, Principal Accounting Officer & General Counsel1.08yrsUS$1.86m0.047%
$ 56.3k
Gavin Corcoran
Chief R&D Officer of Axovant Sciences2.08yrsUS$1.46m0.024%
$ 29.1k
Fraser Wright
Chief Technology Officer2.58yrsno datano data
Tricia Truehart
Head of Investor Relationsno datano datano data
Marianne L. Dinsmore
Head of Global Transactions & Risk Management5.42yrsUS$1.07mno data
Ilise Lombardo
Chief Medical Officer5.33yrsno datano data
Shankar Ramaswamy
Chief Business Officer2.5yrsno datano data
Parag Meswani
Senior VP of Commercial Strategy & Operations1.75yrsno datano data
Paul Korner
Senior VP of Clinical Development1.75yrsno datano data
Gregory Stewart
Senior VP of Vector Delivery & Optimization1.75yrsno datano data
Michael Hayden
Senior Scientific Advisor & Chairman of the Scientific Advisory Board2.25yrsno datano data

2.3yrs

Average Tenure

57yo

Average Age

Experienced Management: AXGT's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pavan Cheruvu
CEO & Director2.5yrsUS$2.87m0.14%
$ 171.8k
Michael Hayden
Senior Scientific Advisor & Chairman of the Scientific Advisory Board2.25yrsno datano data
Berndt A. Modig
Independent Director5.42yrsUS$232.47k0.024%
$ 28.9k
Atul Pande
Lead Independent Director1.92yrsUS$256.60k0.058%
$ 69.4k
Frank Torti
Chairperson1.92yrsUS$249.60kno data
Ilan Oren
Director2.17yrsno datano data
Senthil Sundaram
Independent Director1.08yrsUS$114.39kno data
Eric Venker
Director0.50yrno datano data

1.9yrs

Average Tenure

41.5yo

Average Age

Experienced Board: AXGT's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AXGT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 77.1%.


Top Shareholders

Company Information

Axovant Gene Therapies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Axovant Gene Therapies Ltd.
  • Ticker: AXGT
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$119.798m
  • Shares outstanding: 40.34m
  • Website: https://www.axovant.com

Number of Employees


Location

  • Axovant Gene Therapies Ltd.
  • 11-12 St. James's Square
  • 3rd Floor
  • London
  • Greater London
  • SW1Y 4LB
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGTNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2015
3ASAMUN (Boerse Muenchen)YesCommon SharesDEEURJun 2015
3ASADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company’s product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene thera ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/06 00:06
End of Day Share Price2020/08/05 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.